Emmecell receives FDA RMAT designation for EO2002, advancing development of its regenerative cell therapy for corneal ...
The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to ...
Sepsis, a life-threatening systemic inflammatory response triggered by infection, has long challenged clinicians with its persistently high mortality (up to 40-50% in septic shock). At the heart of ...
A polygenic risk score (PRS) based on genes associated with endothelial cell function identifies patients at a higher risk of coronary artery disease, according to a new study. The risk score, which ...
The Fuchs endothelial corneal dystrophy market is expected to witness steady growth over the coming years, driven by the rising prevalence of the disease, an aging global population, and increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results